Feb 8, 2024, 05:08
Paolo Tarantino: From no anti-HER2 drugs to a plethora of emerging options
Paolo Tarantino, Research Fellow at Dana-Farber Cancer Institute, shared a post on Twitter/X:
“From no anti-HER2 drugs to a plethora of emerging options: promising days for targeting HER2+ colorectal cancer with TKIs, mAbs and ADCs. Check out our review on HER2+ CRC, just out in the first issue of ESMO-GI!”
View additional information.
Source: Paolo Tarantino/X
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Nov 8, 2024, 08:45
Nov 8, 2024, 04:44
Nov 7, 2024, 19:46
Nov 7, 2024, 19:43
Nov 7, 2024, 19:36
Nov 7, 2024, 19:32
Nov 7, 2024, 19:28
Nov 7, 2024, 19:24